KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Income from Continuing Operations (2020 - 2023)

Historic Income from Continuing Operations for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to -$47.2 million.

  • AbCellera Biologics' Income from Continuing Operations fell 5772.92% to -$47.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$146.4 million, marking a year-over-year decrease of 19235.36%. This contributed to the annual value of -$162.9 million for FY2024, which is 1124.26% down from last year.
  • According to the latest figures from Q4 2023, AbCellera Biologics' Income from Continuing Operations is -$47.2 million, which was down 5772.92% from -$28.6 million recorded in Q3 2023.
  • Over the past 5 years, AbCellera Biologics' Income from Continuing Operations peaked at $168.6 million during Q1 2022, and registered a low of -$47.2 million during Q4 2023.
  • In the last 4 years, AbCellera Biologics' Income from Continuing Operations had a median value of -$2.5 million in 2020 and averaged $20.5 million.
  • Data for AbCellera Biologics' Income from Continuing Operations shows a peak YoY increase of 570062.11% (in 2021) and a maximum YoY decrease of 69391.01% (in 2021) over the last 5 years.
  • Over the past 4 years, AbCellera Biologics' Income from Continuing Operations (Quarter) stood at $161.2 million in 2020, then plummeted by 62.8% to $59.9 million in 2021, then tumbled by 149.86% to -$29.9 million in 2022, then plummeted by 57.73% to -$47.2 million in 2023.
  • Its Income from Continuing Operations stands at -$47.2 million for Q4 2023, versus -$28.6 million for Q3 2023 and -$30.5 million for Q2 2023.